@Article{,
AUTHOR = {Xiaolong S. Liu, Christine Folia, Leonard G. Gomella},
TITLE = {Pharmacology for common urologic diseases: 2011 review for the primary care physician},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {18},
YEAR = {2011},
NUMBER = {Suppl.2},
PAGES = {24--38},
URL = {http://www.techscience.com/CJU/v18nSuppl.2/63033},
ISSN = {1488-5581},
ABSTRACT = {Coordination of care between the urologist and primary 
care physician is critical to effective treatment of a variety 
of urologic conditions. Medical therapies for benign 
prostatic hyperplasia, erectile dysfunction, hypogonadism, 
overactive bladder, and prostate cancer are widely available 
and a basic understanding of the pathophysiology of these 
disease states as well as the pharmacology of existing 
treatment options are necessary to avoid complications 
and maximize efficacy associated with patient outcomes. 
Important regulatory decisions have been made concerning 
the approval and lack of approval of several important 
urologic medications. Major advances have been made 
in the therapy of castrate resistant prostate cancer as well 
as hormonal related skeletal events secondary to advanced 
carcinoma of the prostate. We provide a 2011 update of 
the available medications for treatment of several common 
urologic diseases.},
DOI = {}
}